These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 3358893)
1. Adverse reactions to the non-drug constituents of nebuliser solutions. Beasley R; Rafferty P; Holgate ST Br J Clin Pharmacol; 1988 Mar; 25(3):283-7. PubMed ID: 3358893 [No Abstract] [Full Text] [Related]
2. A non-bronchoconstrictor, bacteriostatic preservative for nebuliser solutions. Summers QA; Nesbit MR; Levin R; Holgate ST Br J Clin Pharmacol; 1991 Feb; 31(2):204-6. PubMed ID: 2049239 [TBL] [Abstract][Full Text] [Related]
3. Microbial contamination of nebulization solution and its measures. Oie S; Makieda D; Ishida S; Okano Y; Kamiya A Biol Pharm Bull; 2006 Mar; 29(3):503-7. PubMed ID: 16508154 [TBL] [Abstract][Full Text] [Related]
4. Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution. Beasley CR; Rafferty P; Holgate ST Br Med J (Clin Res Ed); 1987 May; 294(6581):1197-8. PubMed ID: 2954609 [No Abstract] [Full Text] [Related]
5. Effect of preservative on the efficacy of terbutaline nebuliser solution in atopic asthma. Lai CK; Chan CH Thorax; 1993 May; 48(5):566-8. PubMed ID: 8322247 [TBL] [Abstract][Full Text] [Related]
7. [Preservatives in nebulizer solutions: risks without benefit]. Hanquin JM J Pharm Belg; 1999; 54(2):38-43. PubMed ID: 10380409 [No Abstract] [Full Text] [Related]
8. Comparison of the efficacy of preservative free ipratropium bromide and Atrovent nebuliser solution. Rafferty P; Beasley R; Holgate ST Thorax; 1988 Jun; 43(6):446-50. PubMed ID: 2971274 [TBL] [Abstract][Full Text] [Related]
9. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Pediatrics; 1997 Feb; 99(2):268-78. PubMed ID: 9024461 [TBL] [Abstract][Full Text] [Related]
10. Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis. Bozdağ S; Gümüş K; Gümüş O; Unlü N Eur J Pharm Biopharm; 2008 Sep; 70(1):260-9. PubMed ID: 18590953 [TBL] [Abstract][Full Text] [Related]
11. Are excipients really inert ingredients? A review of adverse reactions to excipients in oral dermatologic medications in Canada. Noiles K; Vender R J Cutan Med Surg; 2010; 14(3):105-14. PubMed ID: 20487670 [TBL] [Abstract][Full Text] [Related]
12. Call for worldwide withdrawal of benzalkonium chloride from nebulizer solutions. Beasley R; Burgess C; Holt S J Allergy Clin Immunol; 2001 Feb; 107(2):222-3. PubMed ID: 11174185 [No Abstract] [Full Text] [Related]
13. Preservatives in nebulizer solutions: risks without benefit. Beasley R; Fishwick D; Miles JF; Hendeles L Pharmacotherapy; 1998; 18(1):130-9. PubMed ID: 9469687 [TBL] [Abstract][Full Text] [Related]